Table 2 Study data sources including data collector, data collection method, correlation to specific CFIR domain, and target study participant. Matrix of data collection methods
From: Evaluating blinatumomab implementation in low- and middle-income countries: a study protocol
Type of data | Data collectors | Data collection method | CFIR domain | Study participants |
|---|---|---|---|---|
Primary data | BHAP core team | Hospital assessment questionnaire | Inner setting | Pilot center physician champion |
St. Jude research team | Provider knowledge assessment | Inner setting | Multidisciplinary pilot center providers | |
Organization Readiness for Implementing Change (ORIC) | Intervention characteristics | Pilot center implementation team | ||
Implementation Climate Scale (ICS) | Inner setting | Pilot center implementation team | ||
Complexity of intervention assessment | Intervention characteristics | Pilot center implementation team | ||
Implementation outcome surveys (Feasibility of Intervention Measure, Acceptability of Intervention Measure, Intervention Appropriateness Measure) | Intervention characteristics | Pilot center implementation team | ||
Strategy ranking survey | Process | Pilot center implementation team | ||
Stakeholder interviews (barrier assessment, informed adaptation of patient eligibility criteria and training materials, strategy prioritization, and assessment) | Inner setting Process Intervention characteristics Outer setting | Key stakeholders | ||
Meeting notes | Process | Key stakeholders | ||
Group interview (strategy analysis, feedback on training strategy, implementation outcome, team dynamics, identifying unanticipated challenges, and adaptation of implementation, provider satisfaction) | Inner setting Process Intervention characteristics | Pilot center implementation team | ||
Secondary data | Local site providers | Medication interruption record | Intervention characteristics | Blinatumomab recipients |
Local site providers | Adverse event reporting, severity, and number of events | Intervention characteristics | Blinatumomab recipients | |
Local site providers | Disease outcomes (MRD status, remission status, proceed to transplant, mortality) | Intervention characteristics | Blinatumomab recipients | |
Local site providers | Participant satisfaction | Intervention characteristics | Patient and family | |
Local site providers | Baseline patient characteristics | Intervention characteristics Inner setting | Blinatumomab recipients | |
Local site providers | Delivery cost of blinatumomab | Intervention characteristic | Blinatumomab recipients | |
Process indicators | St. Jude research team | Attendance of training sessions, utilization of web-based resources, and proportion of patients enrolled in the BHAP program | Process | Pilot center providers |